FindTrial
Sign In

Application of Monte Carlo Simulation to Optimize the Dosage Regimen of Meropenem in Pseudomonas Aeruginosa Infection patients with Augmented Renal Clearance

Application of Monte Carlo Simulation to Optimize the Dosage Regimen of Meropenem in Pseudomonas Aeruginosa Infection patients with Augmented Renal Clearance

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072957
Enrollment
Unknown
Registered
2023-06-28
Start date
2022-04-15
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pseudomonas aeruginosa infection with renal hyperactivity

Interventions

low-dose group/middle-dose group/high-dose group:N/A

Sponsors

Weihai Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: To accurately screen for ARC, patients' renal function needs to be continuously monitored. Based on the patients' serum creatinine values recorded in the hospital test information system, clinical pharmacists used the Ccockcroft-Gault (C-G) formula to calculate CrCl, and after several evaluations, patients with CrCl >130 mL-min-1-1.73 m-2 were screened as study subjects, and patients with Meropenem for treatment of Pseudomonas aeruginosa in patients with ARC were included in the experimental group.

Exclusion criteria

Exclusion criteria: Patients with a history of renal insufficiency were excluded

Design outcomes

Primary

MeasureTime frame
CRP;white blood cell count;PTA;CFR;—

Countries

China

Contacts

Public ContactJia Hou

Weihai Municipal Hospital

houjiajia888@126.com+86 185 6310 0669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026